Upadacitinib was superior to dupilumab for the treatment of atopic dermatitis in the head and neck, trunk, upper limbs, and lower limbs.

Healing of chronic venous leg ulcers among older adults may be affected by wound-related factors, symptoms, and systemic inflammation.

Ritlecitinib and baricitinib have similar rates of hair regrowth at 24 weeks of treatment in patients with severe alopecia areata.

Predictors of developing PsA among patients with arthralgia at risk for progression included a family history of psoriasis and specific ultrasound features.

Cognitive behavioral therapy and physical and mental health rehabilitation can help improve symptoms of long COVID.

For low-risk pregnancies, planned home births are as safe as planned birth center births, according to study findings.

About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.

Overall, 13.9% of adults age 65 years and older met the federal physical activity guidelines for both aerobic and muscle-strengthening activities in 2022.

Several adverse health outcomes are associated with AD, such as atopic and allergic conditions, immune mediated conditions, and more.

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

From 2021 to 2022, there was a decrease in the number of abortions performed, as well as in the abortion rate and ratio.